MDWD - MediWound Ltd.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$28.50
DETAILS
HIGH:
$30.00
LOW:
$27.00
MEDIAN:
$28.50
CONSENSUS:
$28.50
UPSIDE:
131.43%
About MediWound Ltd. (https://www.mediwound.com)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Ofer Gonen | Chief Executive Officer | 1973 | $834,000 USD |
| Ety Klinger | Chief Medical Officer | 1962 | $428,000 USD |
| Shmulik Hess | Chief Operating Officer & Chief Commercial Officer | 1974 | $426,000 USD |
| Hani Luxenburg | Chief Financial Officer | 1974 | $420,000 USD |
| Yaron Meyer Adv. | Executive Vice President, General Counsel & Corporate Secretary | 1979 | $337,000 USD |
| Barry J. Wolfenson | Executive Vice President of Strategy & Corporate Development | 1967 | – |
| Liron Gal | Vice President of Manufacturing Science & Technology | – | – |
| Robert J. Snyder FFPM | Senior Vice President of Global Medical Affairs | 1951 | – |